A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease.

A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease.

Abnormal motor behaviors in Parkinson’s disease (PD) result from striatal dysfunction due to an imbalance between dopamine and glutamate transmissions that are integrated by dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). c-Abelson tyrosine kinase (c-Abl) phosphorylates cyclin-depe...

Full description

Bibliographic Details
Main Authors: Akie eTanabe, Yukio eYamamura, Jiro eKasahara, Ryoma eMorigaki, Ryuji eKaji, Satoshi eGoto
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-02-01
Series:Frontiers in Cellular Neuroscience
Subjects:
Cyclin-Dependent Kinase 5
Parkinson's disease
DARPP-32
CDK5
nilotinib
c-Abl inhibitor
Online Access:http://journal.frontiersin.org/Journal/10.3389/fncel.2014.00050/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fncel.2014.00050/full

Similar Items